Trials / Unknown
UnknownNCT05803642
A Study of Olanzapine in Patients With Acute Agitation
A Multicenter, Randomized, Double-blind, Parallel-controlled Injection of Olanzapine in the Treatment of Acute Agitation Associated With Schizophrenia and Bipolar I Disorder.
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 318 (estimated)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of intramuscular olanzapine for the treatment of acute agitation associated with schizophrenia and bipolar I mania.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olanzapine | intramuscular injection, 10 mg/dose, first dose and an optional second or third dose. |
| DRUG | Haloperidol | intramuscular injection, 7.5 mg/dose, first dose and an optional second or third dose. |
Timeline
- Start date
- 2023-03-28
- Primary completion
- 2024-05-07
- Completion
- 2024-07-02
- First posted
- 2023-04-07
- Last updated
- 2023-04-07
Source: ClinicalTrials.gov record NCT05803642. Inclusion in this directory is not an endorsement.